Related Experiment Video
Updated: Sep 30, 2025
05:46
Author Spotlight: Advancements in Refractive Surgical Correction for Presbyopia and Exploring Postoperative Visual Acuity
Published on: September 20, 2024
541
Pharmacological Treatment in Presbyopia
Andrzej Grzybowski1,2, Varis Ruamviboonsuk3
1Department of Ophthalmology, University of Warmia and Mazury, 10-720 Olsztyn, Poland.
Journal of Clinical Medicine
|March 10, 2022
Summary
Pharmacological treatments for presbyopia, including miotics and lens softeners, offer spectacle-free options. While miotics provide temporary vision improvement, their long-term safety and efficacy require further investigation.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Presbyopia, an age-related condition, significantly impacts near vision and quality of life.
- Current management primarily involves corrective lenses, with limited non-invasive treatment options.
Purpose of the Study:
- To review current pharmacological approaches for presbyopia treatment.
- To evaluate the mechanisms, efficacy, and safety of miotic agents and lens softeners.
- To discuss the implications of recent FDA approvals for future research.
Main Methods:
- Literature review of pharmacological agents for presbyopia.
- Analysis of studies on miotic agents (e.g., pilocarpine) and lens softeners.
- Examination of reported adverse events and treatment outcomes.
Main Results:
- Miotics induce a temporary pinhole effect, improving depth of focus but causing temporary side effects like dim vision.
- Lens softeners aim to restore lens elasticity, but clinical trial results are inconclusive.
- The US FDA approval of 1.25% pilocarpine marks a significant step for real-world data collection.
Conclusions:
- Pharmacological treatments offer a spectacle-free alternative for presbyopia with potentially lower risks than surgery.
- Further research is crucial to establish long-term safety and efficacy of these agents, especially in combination therapies.
- Real-world data will be vital in understanding the clinical utility of approved pharmacological treatments for presbyopia.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
728
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
728
01:28Angle Closure Glaucoma: Treatment
858
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
858
01:16Focusing of Light in the Eye
3.3K
Light rays enter the eye through the cornea, a transparent dome-shaped tissue that is the eye's outermost layer. The cornea bends or refracts, light rays traveling to the pupil. The shape of the cornea determines how much of the light is bent and whether the image will be focused correctly on the retina at the back of the eye. Once the light has passed through both refraction layers, it converges into a single focal point onto a small area. This is where photoreceptors start transforming...
3.3K
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.1K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.1K
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.8K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.8K
01:25Glaucoma: Overview
935
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
935